Last Call for canSERV Third Open Call Funding
One document
more
Stories about Krankheit
Event Announcement: VIROFIGHT Hybrid Symposium
One documentmoreLaunch of canSERV Call for Service Provision – "Training the Next Generation of Cancer Researchers"
One documentmore- 2
Fundació Puigvert validates a new tool capable of selecting the most suitable antibiotic for uncomplicated urinary tract infections within 45 minutes.
One documentmore - 2
Record financing rounds at the Munich biotech hub
One documentmore canSERV relaunches Open Call for Service Provision
One documentmorePress release: STADA continues strong growth journey in the first half of 2024
One documentmorecanSERV to Accelerate Your Cancer Research - 2 Calls for Service Provision Open
2 Documentsmore- 4
Sysmex’s PA-100 AST System Wins One of the UK’s Biggest Science Prizes
One documentmore Press release: Alvotech and STADA add to strategic alliance through denosumab partnership
Alvotech and STADA add to strategic alliance through denosumab partnership - STADA assumes marketing license for Alvotech’s proposed biosimilar referencing Prolia®/Xgeva® (denosumab) in Europe, including Switzerland and the UK, as well as rights in selected markets in Central Asia and the Middle ...
One documentmorePress release: STADA welcomes CHMP positive opinion on extending indication for Kinpeygo
STADA welcomes CHMP positive opinion on extending indication for Kinpeygo - The CHMP adopted a positive opinion recommending a change to the terms of the marketing authorization of Kinpeygo for the treatment of adults with primary immunoglobulin A, now covering patients with a UPCR of ≥0.8 g/g - ...
One documentmorePress release: Bio-Thera and STADA Reach Exclusive Agreement for BAT2506, a Proposed Golimumab Biosimilar, in the EU and UK
Bio-Thera and STADA Reach Exclusive Agreement for BAT2506, a Proposed Golimumab Biosimilar, in the EU and UK - Bio-Thera and STADA have reached an exclusive commercialization and license agreement for BAT2506, a biosimilar candidate to Simponi® ...
One documentmorecanSERV invites applications for "Revolutionising Cancer Patient Care"
One documentmore- 3
canSERV invites applications for "Revolutionising Cancer Patient Care"
One documentmore LAST CHANCE: canSERV Second Open Call for Cancer Research Service Provision
One documentmore- 3
canSERV Initiative: EU Consortium Launches Groundbreaking Call to Accelerate Cancer Research
One documentmore Press release: STADA continues with double-digit sales and profit growth in 2023
One documentmoreLeipzig Tourismus und Marketing GmbH
5Pioneering Heart Surgery and Medical Congresses in Leipzig
One documentmoreStrengthening the Direct Sales and Service System for Business Expansion in Italy
One documentmorePress release: STADA and Alvotech secure approval for Uzpruvo, Europe’s first ustekinumab biosimilar to Stelara
STADA and Alvotech secure approval for Uzpruvo, Europe’s first ustekinumab biosimilar to Stelara - Marketing authorization issued in European Economic Area for Uzpruvo®, the first biosimilar to Stelara®, a biologic therapy within ...
One documentmore- 3
EU Provides 1 Mio. to Researchers to Advance Personalised Oncology
One documentmore canSERV Releases Open Call for Transnational Service Provision
One documentmore- 2
Press release : People with Parkinson’s experience variations in effects of oral medicines, but lack advice, international survey reveals
One documentmore - 2
Press release: STADA's excellent results in H1 2023 indicate a record annual profit of €1 bn, driven by Consumer Healthcare and Specialty
One documentmore - 5
Press Release - hubergroup India expands its support for rural healthcare
One documentmore Free Access to Cancer Research Services - canSERV 1st Call for Proposals
One documentmoreInnovation and Start-up Center Biotechnology (IZB) welcomes Invitris
One documentmorePress release: EMA Confirms Acceptance of Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab)
EMA Confirms Acceptance of Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab) - Partners Alvotech and STADA have marketing authorization application (MAA) for ustekinumab accepted for filing by the European Medicines Agency (EMA) ...
One documentmorePress release: Alvotech and STADA Broaden Access to Adalimumab Biosimilar in Europe
Alvotech and STADA Broaden Access to Adalimumab Biosimilar in Europe - Launches in Belgium, Bulgaria, Croatia, Czech Republic, Latvia, Romania, and Slovenia, increasing availability of high-concentration, citrate-free adalimumab in Europe - Follows initial introduction of adalimumab in ninecountries: ...
One documentmoreInnovation and Start-Up Center for Biotechnology (IZB) welcomes new start-up Origin.Bio
One documentmore
12Next